Summary
Despite modern therapy, one third to one half of patients who get breast cancer will eventually die from it. This disconcerting circumstance has focused attention on prevention, and preventing breast cancer will require a much better understanding of the biological abnormalities underlying its development and progression. Many studies into the mechanisms of invasive breast cancer evolution have evaluated presumed precursor lesions (e.g. proliferative disease without atypia, atypical ductal hyperplasia, and ductal carcinoma in-situ) for genetic alterations known to occur in fully developed invasive carcinomas. This approach has shed some light on events which may be important in early malignant transformation, including the observations that overexpression of the c-erbB-2 oncogene and mutations of the p53 tumor suppressor gene are present in significant subsets of DCIS, but not PDWA or ADH. Although this approach is limited by our incomplete knowledge of cancer genetics, there is still a great deal to learn about breast cancer evolution by evaluating cancer-associated genes in potential precursor lesions using established techniques such as immunohistochemistry and in situ hybridization.
Similar content being viewed by others
References
Fearon ER, Vogelstein B: A genetic model for colorectal tumorigenesis. Cell 61:759–767, 1990.
O'Connell P, Pekkel V, Fuqua SAW, Osborne CK, Allred DC: Molecular genetic studies of early breast cancer evolution by LOH. Breast Cancer Res Treat (this issue).
Bartow SA, Pathak DR, Black WC, Key CR, Teaf SR: Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study. Cancer 60:2751–2760, 1987.
Dupont WE, Page DL: Risk factors for breast cancer in women with proliferative breast disease. N Engl J Med 312:146–151, 1985.
London SJ, Connolly JL, Schnitt SJ, Colditz GA: A prospective study of benign breast disease and the risk of breast cancer. J Am Med Assoc 267:941–944, 1992.
Palli D, Roselli del Turco M, Simoncini R, Bianchi S: Benign breast disease and breast cancer: A case-control study in a cohort in Italy. Int J Cancer 47: 703–706, 1991.
Kintanar EB, Raju U: Further delineation of patterns of atypical ductal hyperplasia: An analysis of ADH patterns associated with intraductal and invasive breast carcinoma. Mod Pathol 4:12A, 1991.
Alpers CE, Wellings SR: The prevalence of carcinoma in situ in normal and cancer-associated breasts. Human Pathol 16:796–807, 1985.
Jacquemier JD, Hassoun J, Torrente M, Martin PM: Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages — immunohistochemical study of 107 cases. Breast Cancer Res Treat 15:109–117, 1990.
Barnes R, Masood S: Potential value of hormone receptor assay in carcinoma in situ of breast. Am J Clin Pathol 94:533–537, 1990.
Poller DN, Snead DRJ, Roberts EC, et al: Oestrogen receptor expression in ductal carcinoma in-situ of the breast: relationship to flow cytometric analysis of DNA and expression of the c-erbB-2 oncoprotein. Br J Cancer 68:156–161, 1993.
Meyer JS: Cell kinetics of histologic variants of in-situ breast carcinoma. Breast Cancer Res Treat 7:171–180, 1986.
Aasmundstad TA, Haugen OA: DNA ploidy in intraductal breast carcinomas. Eur J Cancer 26:956–959, 1990.
Killeen JL, Namiki H: DNA analysis of ductal carcinoma in situ of the breast. Cancer 68:2602–2607, 1991.
Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Price P, McKinna A, Harrison S: Immunohistochemical distribution of c-erbB-2 in infiltrating and in situ breast cancer. Int J Cancer 42:842–845, 1988.
Allred DC, Clark GM, Molina R, Tandon AK, Schnitt SJ, Gilchrist KW, Osborne CK, Tormey DC, McGuire WL: Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer. Human Pathol 23:974–979, 1992.
Gusterson BA, Machin LG, Gullick WJ, Gibbs NM, Powles TJ, Elliott C, Ashley S, Monaghan P, Harrison S: c-erbB-2 expression in benign and malignant breast disease. Br J Cancer 58:453–457, 1988.
Davidoff AM, Kerns BJM, Iglehart JC, Marks JR: Maintenance of p53 alterations throughout breast cancer progression. Cancer Res 51:2605–2610, 1991.
Poller DN, Roberts JA, Bell RA, Elston CW, Blamey RW, Ellis IO: p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erbB-2 protein. Human Pathol 24:463–468, 1993.
Tsutsumi Y, Naber SP, DeLellis RA, et al: neu oncogene protein and epidermal growth factor receptor are independently expressed in benign and malignant breast tissues. Human Pathol 21:750–758, 1990.
Fromowitz FB, Viola MV, Chao S, et al: ras p21 expression in the progression of breast cancer. Hum Pathol 18:1268–1275, 1987.
Watson PH, Safneck JR, Le K, et al: Relationship of c-myc amplification to progression of breast cancer from in situ to invasive tumor and lymph node metastasis. J Natl Cancer Inst 85:902–907, 1993.
Koukoulis GK, Virtanen I, Korhonen M, et al: Immunohistochemical localization of integrins in the normal, hyperplastic, and neoplastic breast. Am J Pathol 139:787–799, 1991.
Smith HS, Lu W, Beng G, et al: Molecular aspects of early stages of breast cancer progression. J Cellular Biochem 176:144–152, 1993.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Allred, D.C., O'Connell, P., Fuqua, S.A.W. et al. Immunohistochemical studies of early breast cancer evolution. Breast Cancer Res Tr 32, 13–18 (1994). https://doi.org/10.1007/BF00666202
Issue Date:
DOI: https://doi.org/10.1007/BF00666202